These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 11157657)
21. Glycoprotein IIB/IIIA inhibitor to reduce postpercutaneous coronary intervention myonecrosis and improve coronary flow in diabetics: the 'OPTIMIZE-IT' pilot randomized study. Talarico GP; Brancati M; Burzotta F; Porto I; Trani C; De Vita M; Todaro D; Giammarinaro M; Leone AM; Niccoli G; Andreotti F; Mazzari MA; Schiavoni G; Crea F J Cardiovasc Med (Hagerstown); 2009 Mar; 10(3):245-51. PubMed ID: 19262211 [TBL] [Abstract][Full Text] [Related]
22. [Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC]. Silber S; Albertsson P; Aviles FF; Camici PG; Colombo A; Hamm C; Jorgensen E; Marco J; Nordrehaug JE; Ruzyłło W; Urban P; Stone GW; Wijns W; Kardiol Pol; 2005 Sep; 63(3):265-320; discussion 321-3. PubMed ID: 16180183 [No Abstract] [Full Text] [Related]
23. Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Pinto DS; Sperling RT; Tu TM; Cohen DJ; Carrozza JP Catheter Cardiovasc Interv; 2003 Jan; 58(1):65-8. PubMed ID: 12508198 [TBL] [Abstract][Full Text] [Related]
25. [Standard pharmacological therapy associated with percutaneous coronary interventions in patients with stable angina]. Karcz M; Ruzyłło W Kardiol Pol; 2004 Nov; 61(11):480-2. PubMed ID: 15883598 [No Abstract] [Full Text] [Related]
26. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? Lincoff AM; Topol EJ Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004 [No Abstract] [Full Text] [Related]
27. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428 [TBL] [Abstract][Full Text] [Related]
28. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P; Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315 [TBL] [Abstract][Full Text] [Related]
29. Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target? Topaz O Catheter Cardiovasc Interv; 2007 Apr; 69(5):630-1. PubMed ID: 17377986 [No Abstract] [Full Text] [Related]
30. Facilitated percutaneous coronary intervention: a novel concept in expediting and improving acute myocardial infarction care. Li RH; Herrmann HC Am Heart J; 2000 Dec; 140(6 Suppl):S125-35. PubMed ID: 11100006 [No Abstract] [Full Text] [Related]
31. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease]. Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681 [TBL] [Abstract][Full Text] [Related]
32. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ; J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319 [TBL] [Abstract][Full Text] [Related]
33. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152 [TBL] [Abstract][Full Text] [Related]
34. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A; Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766 [TBL] [Abstract][Full Text] [Related]
35. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes. Campbell P N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228 [No Abstract] [Full Text] [Related]
36. Safety and efficacy of indigenously developed and manufactured bivalirudin in moderate/high-risk Indian patients undergoing percutaneous coronary intervention: the Bivaflo Registry. Seth A; Sinha N; Parikh K; Patel T; Hiremath MS; Mehta AB; Chandra P; Pinto B; Sethi KK; Sengottuvelu S Indian Heart J; 2008; 60(4):333-41. PubMed ID: 19242012 [TBL] [Abstract][Full Text] [Related]
37. [Oral glycoprotein IIb/IIIa-inhibitors inhibit platelet aggregation: an aid against unstable coronary syndrome and recurrent stenosis after angioplasty. Satellite symposia within the 22nd Congress of the European Cardiology Society]. Dtsch Med Wochenschr; 1998 Oct; 123(44 Suppl):1-6. PubMed ID: 9828729 [No Abstract] [Full Text] [Related]
38. [Glycoprotein IIb/IIIa antagonists]. Hennemann A Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193 [No Abstract] [Full Text] [Related]